Ariad Pharmaceuticals Inc

Entity type image
Type: Company
Name: Ariad Pharmaceuticals Inc
First reported 3 hours ago - Updated 22 mins ago - 1 reports
Deutsche Bank AG
Deutsche Bank AG

Ariad Pharmaceuticals, Inc. to Present at the Deutsche Bank 38th Annual Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Deutsche Bank 38th Annual Healthcare Conference being held in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the ... [Published BioSpace - 3 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

ARIAD to Present at the Deutsche Bank 38th Annual Healthcare Conference

Home » Press Releases » ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Deutsche Bank 38th Annual Healthcare Conference being held in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide ... [Published BioPortfolio - 9 hours ago]
First reported 12 hours ago - Updated 12 hours ago - 1 reports

Why one trader is selling puts in Ariad

Ariad Pharmaceuticals is trying to break out of its recent range, and one trader is betting on a floor beneath the stock.optionMONSTER's tracking systems detected the sale of 2,500 August 15 puts in one print for $0.33. This is clearly a new position, ... [Published Yahoo! Finance - 12 hours ago]
First reported May 22 2013 - Updated May 22 2013 - 1 reports
MannKind Corp
MannKind Corp

Healthcare Review: MannKind Corporation, NPS Pharmaceuticals, Ariad Pharmaceuticals, Bristol Myers Squibb, Celsion Corporation

MannKind Corporation (NASDAQ:MNKD) shares increased 18.66% to $6.36. The company on May 9 posted financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, total operating expenses were $36.4 million, compared to $33.9 ... [Published BioMedReports - May 22 2013]
First reported May 22 2013 - Updated May 22 2013 - 1 reports

Ariad Pharmaceuticals (ARIA) Trading Near $18.16 Resistance Level

Ariad Pharmaceuticals (NASDAQ: ARIA) closed Tuesday's trading session at $17.53. In the past year, the stock has hit a 52-week low of $15.13 and 52-week high of $25.40. Ariad Pharmaceuticals (ARIA) stock has been showing support around $16.36 and resistance ... [Published MarketIntelligenceCenter.com - May 22 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports
Phase II
Phase II

Ariad Pharmaceuticals Inc. Presents at UBS Global Healthcare Conference, May-20-2013 08:30 AM

Matthew Harrison - UBS Investment Bank, Research DivisionGood morning, everybody. I'm Matthew Harrison, the biotech -- one of the biotech analysts here at UBS. Pleased to have ARIAD presenting this morning, and presenting for ARIAD is Harvey Berger, the ... [Published Seeking Alpha - May 20 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports

ARIAD Reports First Quarter 2013 Financial Results and Development Progress

By a News Reporter-Staff News Editor at Clinical Trials Week ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) reported financial results for the first quarter, including revenue from its first cancer medicine, Iclusig (ponatinib), which was approved last December ... [Published Pharmacy Choice - May 20 2013]
First reported May 19 2013 - Updated May 19 2013 - 1 reports

Ariad Pharmaceuticals, Inc. (ARIA), Infinity Pharmaceuticals Inc. (INFI), Oncothyreon Inc (USA) (ONTY): What’s Moving These Biotech Stocks?

As one of the most important conferences in biotechnology approaches (ASCO) we are seeing wild swings of volatility. On Thursday there were several stocks that moved to the downside, and in this piece I am determining if any are a buy after the large ... [Published InsiderMonkey.com - May 19 2013]
First reported May 17 2013 - Updated May 18 2013 - 2 reports

Analysts: Tesla’s Capital Efforts Are Beneficial and 3 More Research Notes to Read

Tesla Motors ( NASDAQ:TSLA ): Morgan Stanley sees Tesla’s efforts to raise capital as being positive, especially in terms of risk, reputation, and growth. It keeps an Overweight rating, and raised its price target from $103 to $109.NEW! Discover a new ... [Published Wall St. Cheat Sheet - May 17 2013]
First reported May 16 2013 - Updated May 16 2013 - 1 reports

Form 4 ARIAD PHARMACEUTICALS For: May 14 Filed by: BERGER HARVEY J M D

StreetInsider.com - Form 4 ARIAD PHARMACEUTICALS For: May 14 Filed by: BERGER HARVEY J M D ... [Published Street Insider - May 16 2013]
First reported May 16 2013 - Updated May 16 2013 - 1 reports

Shares of Ariad Pharmaceuticals Are Moving Lower on 2.5x Above-Average Volume (ARIA)

(Financial News Network On) The price of Ariad Pharmaceuticals shares has slipped to $16.70 (a 2.4% change) on heavy trading volume. Approximately 7.6 million shares have changed hands today vs. average 30-day volume of 3.0 million shares. Unusually ... [Published Individual.com - May 16 2013]
First reported May 16 2013 - Updated May 16 2013 - 2 reports

BlackBerry Overtaken By Windows Phone and 2 Other Hot Stocks to Watch

BlackBerry ( NASDAQ:BBRY ): Current price $14.84For the first time, Microsoft Corporation’s ( NASDAQ:MSFT ) Windows Phone operating system has  surpassed BlackBerry, says IDC . The firm has released its quarterly analysis on the smartphone market, indicating ... [Published Wall St. Cheat Sheet - May 16 2013]

Quotes

More From BioPortfolio on "ARIAD to Present at the Deutsche Bank 38th Annual Healthcare Conference"
ARIAD to Present at the Deutsche Bank 38th Annual Healthcare Conference [Published BioPortfolio - 9 hours ago]
"Today, we report Iclusig revenues for the first time," said Harvey J Berger, M D , chairman and chief executive officer of ARIAD. "The first quarter shows a very strong launch for Iclusig, which demonstrates early adoption of Iclusig in all lines of treatment for adult patients with CML or Ph+ALL that is resistant or intolerant to prior TKI therapy and impressive market penetration into both the community and academic physician settings. Our commercial team has shown that it can compete effectively in this market, and we will build on this momentum as we move forward through the year. Ensuring that Iclusig is available to all resistant or intolerant Ph+ leukemia adult patients in need of this new treatment option - independent of their ability to pay - is our priority." 2013 First Quarter Financial Results Product Revenues NetNet sales of Iclusig were $6.4 million for the quarter ended March 31, 2013
ARIAD Reports First Quarter 2013 Financial Results and Development Progress [Published Pharmacy Choice - May 20 2013]
"Opting for surveillance spares patients, most of who are young men, from the harmful side effects of chemotherapy and radiation without diminishing their chances for a long and healthy life" said ASCO's incoming president, Dr Clifford Hudis, in a statement
New Cancer Tools Help Patients Reconsider Chemo [Published Healthcare Global - May 16 2013]
"We've been really trying for years to be more precise about who needs treatment ... Now we are more able to achieve it" said Swain
New cancer tools allow patients to reconsider chemo [Published Reuters - May 15 2013]

More Content

All (303) | News (112) | Reports (13) | Blogs (62) | Audio/Video (1) | Fact Sheets (1) | Press Releases (114)
sort by: Date | Relevance
Ariad Pharmaceuticals, Inc. to Present at the D... [Published BioSpace - 3 hours ago]
MNKD, CLNT, SSYS and YY added to NASDAQ Active ... [Published StockHouse USA - 7 hours ago]
ARIAD to Present at the Deutsche Bank 38th Annu... [Published BioPortfolio - 9 hours ago]
ARIAD to Present at the Deutsche Bank 38th Annu... [Published Business Wire Health News - 9 hours ago]
Why one trader is selling puts in Ariad [Published Yahoo! Finance - 12 hours ago]
Ponatinib Shows Strong Activity in Medullary Th... [Published Oncology Times - 21 hours ago]
Healthcare Review: MannKind Corporation, NPS Ph... [Published BioMedReports - May 22 2013]
Ariad Pharmaceuticals (ARIA) Trading Near $18.1... [Published MarketIntelligenceCenter.com - May 22 2013]
Ariad Pharmaceuticals Inc. Presents at UBS Glob... [Published Seeking Alpha - May 20 2013]
ARIAD Reports First Quarter 2013 Financial Resu... [Published Pharmacy Choice - May 20 2013]
Tackling Cancer: Leukemia's Biggest Current and... [Published Motley Fool Discussion Boards - May 19 2013]
Ariad Pharmaceuticals, Inc. (ARIA), Infinity Ph... [Published InsiderMonkey.com - May 19 2013]
Ariad Pharmaceuticals, Inc. (ARIA) - Pharmaceut... [Published TransWorldNews - May 18 2013]
Bellicum in Trials with Cancer Vaccine, Cell-Su... [Published Oncology Business Review - May 17 2013]
Analysts: Tesla’s Capital Efforts Are Beneficia... [Published Wall St. Cheat Sheet - May 17 2013]
Analysts: Tesla’s Capital Efforts Are Beneficia... [Published Wall St. Cheat Sheet - May 17 2013]
Form 4 ARIAD PHARMACEUTICALS For: May 14 Filed ... [Published Street Insider - May 16 2013]
Shares of Ariad Pharmaceuticals Are Moving Lowe... [Published Individual.com - May 16 2013]
BlackBerry Overtaken By Windows Phone and 2 Oth... [Published Wall St. Cheat Sheet - May 16 2013]
BlackBerry Overtaken By Windows Phone and 2 Oth... [Published Wall St. Cheat Sheet - May 16 2013]
Ariad Pharmaceuticals Falling Today on Above-Av... [Published Comtex SmarTrend - May 16 2013]
Ariad Pharmaceuticals (ARIA) Showing Bearish Te... [Published MarketIntelligenceCenter.com - May 16 2013]
Bellicum in Trials with Cancer Vaccine, Cell-Su... [Published Xconomy - May 16 2013]
ARIAD to Take Part in UBS Global Healthcare Con... [Published Individual.com - May 16 2013]
New Cancer Tools Help Patients Reconsider Chemo [Published Healthcare Global - May 16 2013]
New cancer tools allow patients to reconsider c... [Published Reuters - May 15 2013]
ARIAD Announces Data Presentations and Webcast ... [Published Zecco - May 15 2013]
ARIAD Announces Data Presentations and Webcast ... [Published Business Wire Health News - May 15 2013]
ARIAD Pharmaceuticals' CEO Presents at Bank of ... [Published Seeking Alpha - May 15 2013]
2 Biotech Companies With Strong Product Launche... [Published Seeking Alpha - May 15 2013]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
Harvey J. Berger, Harvey Berger, Jim Birchenough, [more]
  •  
MannKind Corp, UBS AG, Bank of America Merrill Lynch, [more]
  •  
University of Newcastle Upon Tyne, FDA Food & Drug Administration, American Association For Cancer Research, [more]
  •  
Ponatinib, Healthcare Conference, chronic myeloid leukemia, [more]
  •  
Boost, Gleevec, BlackBerry, [more]
  •  
Lausanne (Switzerland), Cambridge (Massachusetts, United States), New York City, [more]
  •  
United Kingdom, Switzerland, United States, [more]
  •  
Diseases, Narcotics, Medication, [more]
  •  
IT, Real Estate, Telecom, [more]
MarketIntelligenceCenter.com, Business Wire Health News, EON Health & Medicine, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Ariad Pharmaceuticals (ARIA) Trading Near $18.1... [Published MarketIntelligenceCenter.com - May 22 2013]
Ariad Pharmaceuticals (NASDAQ: ARIA) closed Tuesday's trading session at $17.53. In the past year, the stock has hit a 52-week low of $15.13 and 52-week high of $25.40. Ariad Pharmaceuticals (ARIA) stock has been showing support around $16.36 and resistance ...
Analysts: Tesla’s Capital Efforts Are Beneficia... [Published Wall St. Cheat Sheet - May 17 2013]
Tesla Motors ( NASDAQ:TSLA ): Morgan Stanley sees Tesla’s efforts to raise capital as being positive, especially in terms of risk, reputation, and growth. It keeps an Overweight rating, and raised its price target from $103 to $109.NEW! Discover a new ...
Analysts: Tesla’s Capital Efforts Are Beneficia... [Published Wall St. Cheat Sheet - May 17 2013]
Tesla Motors ( NASDAQ:TSLA ): Morgan Stanley sees Tesla’s efforts to raise capital as being positive, especially in terms of risk, reputation, and growth. It keeps an Overweight rating, and raised its price target from $103 to $109. NEW! Discover ...
BlackBerry Overtaken By Windows Phone and 2 Oth... [Published Wall St. Cheat Sheet - May 16 2013]
BlackBerry ( NASDAQ:BBRY ): Current price $14.84For the first time, Microsoft Corporation’s ( NASDAQ:MSFT ) Windows Phone operating system has  surpassed BlackBerry, says IDC . The firm has released its quarterly analysis on the smartphone market, indicating ...
BlackBerry Overtaken By Windows Phone and 2 Oth... [Published Wall St. Cheat Sheet - May 16 2013]
BlackBerry ( NASDAQ:BBRY ): Current price $14.84 For the first time, Microsoft Corporation’s ( NASDAQ:MSFT ) Windows Phone operating system has  surpassed BlackBerry, says IDC. The firm has released its quarterly analysis on the smartphone market, ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Ariad Gets Boost from Leukemia Drug Approval [Published FOX Business - Video - May 07 2013]
1

Press Releases

sort by: Date | Relevance
ARIAD to Present at the Deutsche Bank 38th Annu... [Published Business Wire Health News - 9 hours ago]
ARIAD Announces Data Presentations and Webcast ... [Published Business Wire Health News - May 15 2013]
ARIAD to Present at UBS Global Healthcare Confe... [Published Business Wire Health News - May 13 2013]
ARIAD Reports First Quarter 2013 Financial Resu... [Published Business Wire - May 07 2013]
ARIAD Reports First Quarter 2013 Financial Resu... [Published Business Wire Health News - May 07 2013]
1 2 3 4 5 6 7 8 9 10 ...
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.